Clinical development of neridronate: potential for new applications

Abstract

Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget’s disease of bone (PDB). A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing a useful system for administration in homecare. In this review, we discuss the latest clinical results of neridronate administration in OI and PDB, as well as in osteoporosis and other conditions. We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I.

Keywords:

• bisphosphonates
• osteogenesis imperfecta
• osteoporosis
• complex regional pain syndrome

Disclosure

Davide Gatti and Maurizio Rossini have received speaking fees from Amgen, Abiogen, Merck, Eli-Lylli, and Pfizer. Ombretta Viapiana has received speaking fees from Abiogen, Merck, and Pfizer. Luca Idolazzi has received speaking fees from Novartis. Silvano Adami is consultancy honoraria for Merck, and Amgen, and has received speaking fees from Amgen, Abiogen, Merck, Eli-Lylli, Pfizer, Novartis, and GSK.